• 1
    American Diabetes Association. Diabetes Statistics. Available from: (accessed 17 February 2006).
  • 2
    American Diabetes Association. Diabetes and Nephropathy (Kidney Complications). Available from: (accessed 17 February 2006).
  • 3
    Lewis MJ, St Peter WL, Kasiske BL. Pathophysiology and therapeutics of progressive renal disease. In: Dipiro, JT, Talbert, RL, Yee, GC, eds. Pharmacotherapy: A Pathophysiologic Approach, 5th edn. New York: McGraw-Hill, 2002:797814.
  • 4
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 14561462.
  • 5
    Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotenisve type 2 diabetic patients with microabluminuria. Diabetes Care 1997; 20: 15761581.
  • 6
    The EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microabluminuria. Lancet 1997; 349: 17871792.
  • 7
    Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982988.
  • 8
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE Study and MICRO-HOPE Sub-Study. Lancet 2000; 355: 253259.
  • 9
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851860.
  • 10
    Brenner BM, Cooper ME, Zeeuw DD, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861869.
  • 11
    Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870878.
  • 12
    American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27: S79S83.
  • 13
    National Kidney Foundation. NKF K/DOQI Guidelines. Available from: (accessed 17 February 2006).
  • 14
    Mckelvie RS, Yusuf S, Pericak D, Gomis R, Andersen S, Arner P. Comparison of candesartan, enalapril, and their combination in congestive heart failure. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 10561064.
  • 15
    Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomised controlled trial of the dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 14401444.
  • 16
    Jacobsen P, Anderson S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992999.
  • 17
    Jacobsen P, Anderson S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin–angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kid Int 2003; 63: 18741880.
  • 18
    Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dialysis Transplant 2002; 17: 10191024.
  • 19
    Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26: 22682274.
  • 20
    Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin–angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25: 95100.
  • 21
    Kim MJ, Song JH, Suh JH, Lee SW, Kim GA. Additive anti-proteinuric effect of combination therapy with ACE inhibitor and angiontensin receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy. Yonsei Med J 2003; 44: 463472.
  • 22
    Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H et al. Anti-proteinuric effects of combined anti-hypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2002; 25: 849855.
  • 23
    Hebert LA, Falkenhain M, Nohman N, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist in diabetic nephropathy. Am J Nephrol 1999; 19: 16.
  • 24
    Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type II diabetes. Int J Clin Pract 2004; 58: 432435.
  • 25
    Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetologia 2001; 38: 157161.
  • 26
    Agarwal A. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001; 59: 22822289.
  • 27
    Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y et al. Combination of half-doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertension 2005; 18: 1317.
  • 28
    Cochrane Collaboration. IMS Homepage. Information Management System. Available from: (accessed 17 February 2006).
  • 29
    Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diabetes Care 2005; 28: 273277.
  • 30
    Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387392.
  • 31
    Imig JD. ACE inhibition and bradykinin-mediated renal vascular responses. Hypertension 2004; 43: 533.
  • 32
    Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117124.
  • 33
    Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD et al. Effect of inhibitors of the renin–angiotensin system and other anti-hypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 20262033.
  • 34
    Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D. Dual renin–angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62: 10201025.